BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 37476077)

  • 1. Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant
    Oliva A; Campogiani L; Savelloni G; Vitale P; Lodi A; Sacco F; Imeneo A; Volpicelli L; Polani R; Raponi G; Sarmati L; Venditti M
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad327. PubMed ID: 37476077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations.
    Oliva A; Al Ismail D; Arcari G; Miele MC; Casali E; Sacco F; Volpicelli L; De Angelis M; Mascellino MT; Cancelli F; Raponi G; Carattoli A; Venditti M
    J Glob Antimicrob Resist; 2023 Jun; 33():321-327. PubMed ID: 37086891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022).
    Boattini M; Bianco G; Bastos P; Comini S; Corcione S; Almeida A; Costa C; De Rosa FG; Cavallo R
    Eur J Clin Microbiol Infect Dis; 2024 Jan; 43(1):155-166. PubMed ID: 37985552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
    Kang Y; Zhou Q; Cui J
    J Glob Antimicrob Resist; 2021 Dec; 27():67-71. PubMed ID: 34428596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
    Guzmán-Puche J; Pérez-Nadales E; Pérez-Vázquez M; Causse M; Gracia-Ahufinger I; Mendez-Natera A; Allalou-Ruiz Y; Elías C; Oteo-Iglesias J; Torre-Cisneros J; Martínez-Martínez L
    Int J Antimicrob Agents; 2022 Feb; 59(2):106524. PubMed ID: 35038557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated
    Qiao S; Xin S; Zhu Y; Zhao F; Wu H; Zhang J; Yao B; Yu Y; Fu Y; Jiang Y; Xie X; Zhang J
    Microbiol Spectr; 2024 Jul; ():e0025824. PubMed ID: 38958437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristic of KPC-12, a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in the Carbapenem-Resistant
    Han W; Zhou P; Chen C; Wu C; Shen L; Wan C; Xiao Y; Zhang J; Wang B; Shi J; Yuan X; Gao H; Wang H; Zhou Y; Yu F
    Infect Drug Resist; 2024; 17():2541-2554. PubMed ID: 38933778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
    Köle M; Sesli Çetin E; Şirin MC; Cicioğlu Arıdoğan B
    Mikrobiyol Bul; 2022 Apr; 56(2):230-250. PubMed ID: 35477227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms Driving the
    Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
    mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem/vaborbactam activity
    Romanelli F; Stolfa S; Morea A; Ronga L; Prete RD; Chironna M; Santacroce L; Mosca A
    Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.
    Shen S; Tang C; Ding L; Han R; Yin D; Yang W; Guo Y; Hu F
    mSphere; 2022 Dec; 7(6):e0048722. PubMed ID: 36374086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity of Ceftazidime-Avibactam Resistance Mechanism in KPC2-Producing
    Jiang M; Sun B; Huang Y; Liu C; Wang Y; Ren Y; Zhang Y; Wang Y; Mu D
    Infect Drug Resist; 2022; 15():4627-4636. PubMed ID: 36003991
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Wang C; Zhao J; Liu Z; Sun A; Sun L; Li B; Lu B; Liu Y; Cao B
    Front Microbiol; 2021; 12():727946. PubMed ID: 34630354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic evolution of ceftazidime-avibactam resistance due to interchanges between
    Chen Y; Yang R; Guo P; Liu P; Deng J; Wu Z; Wu Q; Huang J; Liao K
    Front Cell Infect Microbiol; 2023; 13():1244511. PubMed ID: 37671146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.
    van Asten SAV; Boattini M; Kraakman MEM; Bianco G; Iannaccone M; Costa C; Cavallo R; Bernards AT
    J Infect Chemother; 2021 May; 27(5):778-780. PubMed ID: 33558042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in a Widespread ST11 Carbapenem-Resistant
    Li X; Quan J; Ke H; Wu W; Feng Y; Yu Y; Jiang Y
    Front Microbiol; 2021; 12():724272. PubMed ID: 34484166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.